ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1705

The Lectin Pathway of Complement – a Potential Role in the Pathogenesis and Disease Manifestations of Systemic Sclerosis

Michael Osthoff1,2, Gene-Siew Ngian2,3,4, Melinda Dean5, Mandana Nikpour6, Wendy Stevens7, Susanna Proudman8, Damon Eisen1 and Joanne Sahhar3,9, 1Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Australia, 2Department of Medicine, The University of Melbourne, Melbourne, Australia, 3Department of Rheumatology, Monash Medical Centre, Clayton, Australia, 4Department of Rheumatology, Royal Melbourne Hospital, Parkville, Australia, 5Research and Development, Australian Red Cross Blood Service, Brisbane, Australia, 6Department of Medicine (St Vincent's Hospital), University of Melbourne, Fitzroy, Australia, 7Department of Rheumatology, St. Vincent’s Hospital, Fitzroy, Australia, 8Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, 9Monash Health, Melbourne, Australia

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: complement deficiency and systemic sclerosis, Mannose binding lectin (MBL)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Repetitive episodes of ischemia and reperfusion (I/R) are a cardinal feature of the pathogenesis of systemic sclerosis (SSc), which precedes tissue fibrosis. The complement system is a key mediator of tissue damage after I/R, primarily by activation of the lectin pathway. This study investigated whether serum levels and polymorphisms of mannose-binding lectin (MBL) and ficolin-2 (FCN2), two pattern recognition receptors of the lectin pathway, are associated with the predisposition to, and clinical features of SSc.

Methods:

A case-control study was undertaken involving 90 patients with SSc according to the American College of Rheumatology (73/90) or the LeRoy and Medsger criteria (17/90) from a single SSc outpatient clinic and 90 age- and sex-matched blood donors. MBL and FCN2 levels and polymorphisms were measured in both groups, and in cases correlated with clinical data.

Results:

MBL levels and genotypes were equally distributed in cases and controls while there were some significant differences in FCN2 polymorphisms. Median MBL levels were higher in SSc cases with diffuse disease compared to controls (2.6 vs. 1.0 µg/ml, p<0.001).

In cases, higher MBL levels were associated with the presence of clinical findings associated with vascular dysfunction and local tissue damage (digital ulcers, calcinosis and pitting). Moreover, MBL levels were associated with fibrotic disease manifestations as evidenced by the presence of diffuse disease (median 2.6 vs. 0.8 µg/ml, p=0.002), the modified Rodnan skin score (r=0.39, p<0.001), and interstitial lung disease as measured by forced vital capacity (r=-0.33, p=0.001).  Importantly, MBL levels also correlated with the SSc Health Assessment Questionnaire scores (r=0.33, p=0.002). Results for FCN2 levels were less striking. Phenotypic MBL results were largely confirmed by analysis of MBL polymorphisms. MBL levels were not associated with the presence of autoantibodies or hypocomplementemia.

Conclusion:

Overall, predisposition to SSc was not influenced by the lectin pathway of complement in our matched case-control study. However, our preliminary data suggest that MBL, and to a lesser extent FCN2 may modulate disease manifestations of SSc, particularly in diffuse cutaneous disease. 

Acknowledgments:

Kathleen Elford, Scleroderma Nurse for her assistance in collection of data and samples. SSc patients were recruited from Monash Health as part of the Australian Scleroderma Cohort Study (ASCS), a longitudinal, prospective study of SSc patients.

 

 


Disclosure:

M. Osthoff,
None;

G. S. Ngian,
None;

M. Dean,
None;

M. Nikpour,
None;

W. Stevens,
None;

S. Proudman,
None;

D. Eisen,
None;

J. Sahhar,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-lectin-pathway-of-complement-a-potential-role-in-the-pathogenesis-and-disease-manifestations-of-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology